Comparison of lung preservation solutions in human lungs using an ex vivo lung perfusion experimental model by Medeiros, Israel L. et al.
BASIC RESEARCH
Comparison of lung preservation solutions in human
lungs using an ex vivo lung perfusion experimental
model
Israel L. Medeiros, Paulo M. Peˆgo-Fernandes, Alessandro W. Mariani, Fla´vio G. Fernandes, Fernando V.
Unterpertinger, Mauro Canzian, Fabio B. Jatene
Hospital das Clı´nicas da Faculdade de Medicina da Universidade de Sa˜o Paulo, Heart Institute (InCor), Thoracic Surgery Department, Sa˜o Paulo/SP, Brazil.
OBJECTIVE: Experimental studies on lung preservation have always been performed using animal models. We
present ex vivo lung perfusion as a new model for the study of lung preservation. Using human lungs instead of
animal models may bring the results of experimental studies closer to what could be expected in clinical practice.
METHOD: Brain-dead donors whose lungs had been declined by transplantation teams were used. The cases were
randomized into two groups. In Group 1, PerfadexHwas used for pulmonary preservation, and in Group 2, LPDnac, a
solution manufactured in Brazil, was used. An ex vivo lung perfusion system was used, and the lungs were
ventilated and perfused after 10 hours of cold ischemia. The extent of ischemic-reperfusion injury was measured
using functional and histological parameters.
RESULTS: After reperfusion, the mean oxygenation capacity was 405.3 mmHg in Group 1 and 406.0 mmHg in Group
2 (p=0.98). The mean pulmonary vascular resistance values were 697.6 and 378.3 dyn?s?cm-5, respectively (p= 0.035).
The mean pulmonary compliance was 46.8 cm H2O in Group 1 and 49.3 ml/cm H2O in Group 2 (p= 0.816). The mean
wet/dry weight ratios were 2.06 and 2.02, respectively (p= 0.87). The mean Lung Injury Scores for the biopsy
performed after reperfusion were 4.37 and 4.37 in Groups 1 and 2, respectively (p=1.0), and the apoptotic cell
counts were 118.75/mm2 and 137.50/mm2, respectively (p= 0.71).
CONCLUSION: The locally produced preservation solution proved to be as good as PerfadexH. The clinical use of
LPDnac may reduce costs in our centers. Therefore, it is important to develop new models to study lung
preservation.
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INTRODUCTION
When an organ is removed from the human body, the
organ is subjected to ischemic injury, which may result in
temporary or permanent organ dysfunction after transplan-
tation. The role of pulmonary preservation is to minimize
ischemic effects by preserving the functional and morpho-
logical integrity of the lungs, thus improving function after
transplantation. The preservation method adopted by most
centers is pulmonary artery perfusion with a preservation
solution at 4 C˚ due to the technical simplicity and efficacy of
this method (1). This technique is intended to cool the tissue
evenly and to remove blood from the pulmonary vascular
bed, preventing thrombosis and minimizing the cellular
injury caused by macrophages and neutrophils. Several
experimental studies have been conducted in the past two
decades, demonstrating the superiority of extracellular
solutions (Celsior, low-potassium dextran) over intracellular
solutions (Euro-Collins, Wisconsin University) in lung
transplantation (2-4).
Experimental research in the field of pulmonary pre-
servation has always been performed with animal models.
The species and model structures used vary widely, and the
lack of a standardized model hampers the comparison of
different studies.
Experimental models in medium and large animals are
expensive and time consuming. Small animals are less
expensive, and their use enables experiments to be per-
formed in a shorter period of time. In vivo pulmonary
transplantation models in rats are associated with higher
mortality rates, except in centers where this technique is
performed frequently. Cardiac and pulmonary vascular
resistance measurements are difficult to perform in this
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model. Furthermore, anastomotic technical variability ham-
pers the reproducibility of this model in different centers.
Therefore, the isolated pulmonary perfusion model (ex vivo)
has become popular in pulmonary preservation investigation
centers. This model enables the assessment of the pulmonary
function of lungs undergoing different episodes of cold
ischemia without having to transplant them into other
animals.
The improvement of cardiopulmonary bypass and the
development of new perfusion solutions led to a revival of ex
vivo human perfusion at the beginning of the 21st century (5-
8). In this article, we present ex vivo lung perfusion (EVLP) as
a new model for the study of pulmonary preservation (the
comparison of different techniques and preservation solu-
tions). EVLP combines the use of measurements from ex vivo
animal models with the advantage of using human lungs,
therefore bringing experimental research results closer to
what is observed in clinical practice.
MATERIALS AND METHODS
This study was approved by the institutional ethics
committee. We used human lungs from brain-dead donors
that were rejected by pulmonary transplantation teams
based on criteria previously defined by the International
Society for Heart and Lung Transplantation (9).
The en-bloc lung removal technique was the same as
the one used in clinical practice by transplantation teams,
including pulmonary artery trunk cannulation and perfu-
sion with 50 ml/kg of preservation solution at 4 C˚.
This study was a non-inferiority study. The sample size
required in this case is determined based on the goal of
achieving sufficient power (type II error,0.1) to reject the
null hypothesis when the magnitude of effect is very small
and therefore clinically insignificant. This criterion would
result in a very large sample, precluding the use of a
resource-intensive method that involves the harvesting of
human lungs. The sample size calculation was based on
previously published experimental studies involving the
comparison of lung preservation solutions in experimental
models of lung transplantation in dogs and pigs (10-12).
From April 2009 to April 2010, 16 cases were randomized
into two study groups. In Group 1 (eight cases), PerfadexH
(Vitrolife, Go¨teborg, Sweden) was used as the preservation
solution, and in Group 2 (eight cases), LPDnac (Farmotera´pica,
Sa˜o Paulo, Brazil), a preservation solution manufactured in
Brazil with a chemical composition identical to that of
PerfadexH, was used.
After removal, the pulmonary block was transported and
stored at 4 C˚ for 10 hours. Then, reperfusion was started
using the EVLP model as described below.
The pulmonary block was placed on a rigid, transparent
support (XVIVO Chamber; Vitrolife, Sweden). A cannula
with a built-in catheter to enable continuous pulmonary
artery pressure (PAP) monitoring was sutured into the
trunk of the pulmonary artery. An orotracheal tube was
introduced into the trachea and attached with cardiac tape
(Figure 1). A membrane oxygenator was connected to a gas
mixer, which was connected to two cylinders: one contain-
ing oxygen and the other containing a mixture of nitrogen
(93%) and CO2 (7%). When this mixture was applied to the
membrane oxygenator, it functioned as a ‘‘deoxygenator,’’
so that the prime at the inlet of the pulmonary artery had a
gas concentration similar to that of venous blood.
The system, which was composed of tubes, a venous
reservoir, a membrane oxygenator and a centrifuge pump,
was filled with 1500 ml of Steen SolutionH (Vitrolife,
Sweden), an extracellular electrolyte solution containing
albumin and dextran that was developed for EVLP.
The centrifuge pump was connected with low flow
(100 ml/min), the air was removed from the system, and
the circuit was connected to the pulmonary artery cannula.
The pulmonary vein drainage flowed directly to an XVIVO
Chamber, which was connected to the circuit. The flow was
gradually increased until it reached maximum flow, which
was calculated as 40% of the estimated cardiac output (3x
the body surface area). The PAP was monitored and kept
below 20 mmHg throughout the process to minimize the
development of edema. The temperature was slowly
increased until normothermia (37 C˚) was achieved. When
a temperature of 32 C˚ was reached, ventilation was started
under the following parameters: tidal volume of 8 ml/kg
(donor weight), respiratory rate of 7/min, PEEP of 5 cm
H2O and FiO2 of 100%.
After 60 minutes of EVLP, a sample of the perfusate
from the pulmonary artery and another sample from the
pulmonary vein were collected for blood gas analysis.
The following variables were assessed: weight variation
(DP=weight after EVLP–weight before EVLP), oxygenation
capacity (DPO2=PO2 of pulmonary veins-PO2 of pulmonary
artery), pulmonary vascular resistance (PVR= [PAP/
flow]x80) and pulmonary compliance (PC= tidal volume/
[Pplateau-PEEP]). The left lung was isolated, weighed (wet
weight) and placed in a chamber (60 C˚). After 24 hours, it
was weighed once again (dry weight) to calculate the wet/
dry weight ratio.
Mid-lobe biopsies were collected at three timepoints:
during organ harvesting, after 10 hours of cold ischemia and
after 1 hour of EVLP.
Lung fragments were fixed by immersion in 10%
tamponated formalin. After 24 hours, paraffin blocks were
produced, sectioned in 5 mm slices and stained with
hematoxylin–eosin. Lab specimens were evaluated by light
microscopy by a pathologist experienced in pleuropulmon-
ary diseases. The following parameters were analyzed:
Figure 1 - The preparation of the lungs to start EVLP. A silastic
cannula with a built-in pressure catheter was sewn into the
pulmonary artery (the white arrow), and an endotracheal tube
was inserted into the trachea (the black arrow).
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interstitial edema, alveolar edema, arterial thickening,
vascular thrombosis, interstitial fibrosis, alveolar fibrin,
alveolar exudate, alveolar hemorrhage, interstitial hemor-
rhage, inflammatory interstitial infiltrate, pneumocystis,
alveolar macrophages and necrosis. The pathologist ranked
these changes according to their degree as 0, absent; 1, mild;
2, moderate; or 3, severe. The Lung Injury Score (LIS) was
the sum of the values of all parameters.
Specimens of the above-described fragments were also
prepared for immuno-histochemical analysis with the goal
of detecting and quantifying apoptotic cells using the In situ
Cell Death Detection Kit (Roche, Germany). DNA cleavage
occurs during apoptosis, leading to the formation of breaks
in the DNA and of DNA fragments (oligonucleosomes).
These DNA strand breaks can be identified by adding
nucleotides labeled with fluorescein to the free 39-OH
termini of DNA fragments through an enzymatic reaction.
The TUNEL technique (TdT-mediated dUTP nick end labeling)
is based on the capacity of the terminal deoxynucleotidyl
transferase enzyme (TdT) to catalyze the addition of
deoxyuridine triphosphate (dUTP) to the 39-OH termini of
DNA strands. Specimens were examined by fluorescence
microscopy (Axioskop 2 Plus; Carl Zeiss, Germany) using a
590 nm filter. AxioVision digital image processing software
(Carl Zeiss) was used to display images on a monitor with a
0.02 mm2 field, and apoptotic cells were visualized in a
bright green color (Figure 2). The apoptotic cells were
counted in five fields chosen at random (total area of
0.1 mm2; magnification of x400).
A descriptive analysis was performed in which the
distributions of the variables were presented as the means
and standard deviations or as the medians and interquartile
intervals. Group comparisons of donor lung characteristics
were conducted using the chi-square test (or Fisher’s exact
test) for categorical variables and Student’s t-test for
continuous variables. Statistical analysis of the outcome
variables that were collected only once throughout the
study was performed using Student’s t-test or the Mann-
Whitney test. For outcome variables collected at two
different timepoints, repeated measures analysis of variance
(ANOVA) was used. A type I error probability (a) of 0.05
was used for all inferential analyses. Descriptive and
inferential statistical analyses were performed with the
SPSS software, version 17.0.
RESULTS
The mean donor age was 45.6 (¡20) years, and the donors
included nine men and seven women. The lungs of 13 out of
the 16 donors had been rejected due to unsatisfactory
arterial blood gas values (PaO2 below 300 mmHg with FiO2
of 100% and PEEP of 5 cm H2O). Two donors, despite
having satisfactory blood gas tests, were rejected due to
pneumonia, and one donor was declined due to the lack of a
compatible recipient on the waiting list. The most common
causes of death were hemorrhagic stroke (seven donors)
and subarachnoid hemorrhage (four donors). Table 1 shows
that both study groups were similar with respect to the
donor demographic characteristics. Histological analysis of
the lungs suggested that both groups of lungs were
morphologically similar (Table 2).
After 60 minutes of EVLP, there were mean weight gains
of 68.0 g (¡210.8 g) and 56.8 g (¡98.9 g) in Groups I and II
(p= 0.893), respectively. The mean DPO2 of Group I lungs
was 405.3 mmHg (¡52.4 mmHg), and the mean DPO2 of
Group II lungs was 406.0 mmHg (¡43.5 mmHg) [p= 0.98;
Figure 3]. The mean PVR measured after lung reperfusion in
Group I lungswas 697.6 dyn?s?cm-5 (493.0–1040.0 dyn?s?cm-5),
whereas the mean PVR was 378.3 dyn?s?cm-5 (351.8–628.2
dina.s.cm-5) [p=0.035] for Group II. The mean PC at the end of
reperfusion in Group I was 46.8 cmH2O (¡21.0 cmH2O), and
the mean PC in Group II was 49.3 ml/cm H2O (¡21.7 ml/cm
H2O) [p= 0.816]. The mean wet weight-to-dry weight ratios
were 2.06 (¡0.28) and 2.02 (¡0.70) in Groups I and II,
respectively (p=0.87).
The mean LIS, determined based on the biopsy performed
after 10 hours of cold ischemia, was 4.50 (¡2.14) in Group I
and 4.75 (¡1.83) in Group II. For the biopsy performed after
reperfusion using the ex vivo pulmonary assessment model,
the mean LISs were 4.37 (¡1.51) and 4.37 (¡2.88),
respectively (Figure 4). There was no statistically significant
difference in the LIS between groups over time (p = 0.855).
The identification of apoptotic cells by the TUNEL assay
in the pulmonary tissue harvested after the ischemic period
showed an average of 168.75 (¡173.08) apoptotic cells/mm2
Figure 2 - Apoptotic cells photographed under a fluorescence
microscope at high magnification (x400).
Table 1 - The clinical and demographic characteristics of
the donors.
Group 1
(n= 8)
Group 2
(n= 8)
Donors p-value
Gender (M:F) 3:5 6:2 0.315
Age (years) 50.2 (¡19.4) 40.9 (¡20.8) 0.367
BMI (kg/cm2) 26.7 (¡3.7) 25.1 (¡4.3) 0.447
Smoking 3 1 1.000
Pneumonia 4 4 1.000
WBC count (/mm3) 16,710 (¡5244.6) 14,685 (¡3913.7) 0.396
MV (days) 5.9 (¡3.4) 7.8 (¡5.8) 0.439
PaO2 (mmHg)* 206.04 (¡119.25) 181.36 (¡85.01) 0.641
The continuous variables are expressed as the means (¡standard
deviation), and the categorical variables are expressed as the absolute
number.
*Arterial blood gas analysis performed with FiO2 100% and PEEP 5 cm
H2O.
BMI =body mass index, WBC=white blood cell, MV=mechanical
ventilation.
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in Group I and 200.00 (¡160.36) apoptotic cells/mm2 in
Group II. In the tissue harvested after reperfusion, mean
numbers of 137.50 (¡99.10) and 118.75 (¡99.78) apoptotic
cells/mm2 were observed, respectively. There were no
statistically significant differences in the apoptotic cell
counts between groups over time (p = 0.903).
DISCUSSION
The great success achieved by pulmonary transplantation
in the past decades is partially due to the improvement in
preservation techniques. The aim of these techniques is to
minimize deleterious ischemic effects and reduce the
incidence of graft failure after implantation. Several clinical
and experimental studies have demonstrated that the most
efficient strategy is the hypothermic perfusion of the lungs
with a preservation solution. Nevertheless, primary graft
dysfunction is still observed in 11% to 25% of recipients and
is responsible for 30% of deaths in the first 30 days after
transplantation, indicating that further investigation in the
field of pulmonary preservation is required to improve both
the techniques and the preservation solutions.
Research conducted in the area of pulmonary preservation
has always used animal models. Experiments using medium
and large animals are expensive and time consuming. In
theory, bilateral pulmonary transplantation would be the
method of choice to study pulmonary preservation; however,
intraoperative mortality is very high. The need for a
cardiopulmonary bypass machine and the technical difficulty
of the procedure relative to other methods render bilateral
transplantation inadequate for routine use in experimental
research. The disadvantages of bilateral pulmonary trans-
plantation are the reason why most pulmonary preservation
studies using large animals involve unilateral transplantation.
However, transplantation per se is not an acceptable method
because the normal contralateral lung remains. The presence
of the normal lung may lead to normal functional and
hemodynamic results, even when the transplanted lung has
not been preserved in a satisfactory manner. Therefore, it is
necessary to perform a pneumonectomy or a contralateral
pulmonary artery ligature so that the animal becomes
dependent on the transplanted lung. However, these proce-
dures are associated with cardiac overload, high hemody-
namic instability and high mortality rates.
Experiments using small animals cost less, and a larger
number of experiments can be performed within a shorter
period of time. Isolated pulmonary perfusion models have
become popular due to the technical difficulties associated
with pulmonary transplantation in rats. This model enables
the evaluation of lung function without the need for
transplantation into other animals. The technique consists of
en-bloc ex vivo pulmonary perfusion using venous blood.
Physiological parameters (such as oxygenation, compliance
and pulmonary vascular resistance) can be measured, allow-
ing the comparison of different techniques and preservation
solutions.
The current EVLP model in humans was developed by
Steen et al. in Sweden to evaluate and recondition lungs
removed from ‘‘marginal’’ donors or non-heart-beating
donors (5-7). The method was improved by other groups
and is currently used in several centers for the ex vivo
assessment and recovery of lungs rejected for transplantation
(13,14).
In this study, we demonstrated the feasibility of the EVLP
model for comparing preservation solutions in human
Table 2 - The histological features of the donor lungs.
Group 1
(n= 8)
Group 2
(n= 8)
p-value
LIS* 3.8 (¡2.8) 3.9 (¡2.4) 0.925
Apoptotic cells
(/mm2)#
175 (0-62.5) 200 (75-562.5) 0.561
*Mean¡standard deviation.
#Median (interquartile range).
LIS = lung injury score.
Figure 3 - The oxygenation capacity after reperfusion (DPO2) in both groups (p=0.98). The PaO2 is expressed in mmHg. The error bars
represent the 95% CI.
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lungs, providing results closer to those obtained in clinical
practice without putting real-life patients at risk.
With the aim of verifying the quality of a new preserva-
tion solution for clinical purposes – LPDnac – that was
manufactured by a national lab, we decided to test this
solution in our pulmonary perfusion model in rats (15).
After this first stage, before using it in patients, we decided
to test it in human lungs, using the EVLP model. This model
has offered very consistent and reliable results.
PerfadexH, a preservation solution that is considered to be
the gold standard for pulmonary preservation, was used as
a control. Both analyzed groups consisted of lungs donated
and rejected for transplantation. The groups were similar
with respect to functional and histological characteristics,
and therefore, the differences found after reperfusion could
be attributed to the quality of the pulmonary preservation.
The degree of pulmonary edema is inversely proportional
to the preservation quality. Therefore, variables indicating
edema formation, such as the variation in the wet/dry
weight ratio, are present in most pulmonary preservation
studies. In our study, these variables show similar values in
both groups. Oxygenation capacity is the most important
parameter for functional assessment because, physiologi-
cally, the primary role of the lungs is gas exchange. Our
results demonstrated that the oxygenation capacity was
similar in both groups, showing that the quality of
pulmonary preservation obtained with LPDnac is equiva-
lent to that obtained with PerfadexH. This result is similar to
what was found in a study by Soares PRO (15). In ischemia-
reperfusion injury, there is a reduction in pulmonary
compliance due to the development of alveolar and
interstitial edema. In our study, the results for this variable
are consistent with previously described results: there were
no differences in compliance between the groups. One of the
variables analyzed was discrepant. We noticed a smaller
PVR in the group of lungs preserved with LPDnac. Because
the two groups were similar and because the procedures
were performed by the same team, we could not attribute
this difference to technical aspects. Because the p-value was
borderline, it is possible that this difference occurred by
chance and may disappear if the sample size were greater.
Pulmonary ischemia is associated with a series of
histological alterations, including alveolar edema, the
rupture and thickening of the alveolar-capillary membrane
and focal hemorrhage. We used a score based on the semi-
quantitative analysis of changes observed by conventional
light microscopy. Both groups had the same degree of tissue
injury after cold ischemia and after reperfusion.
There was a small number of apoptotic cells in the lungs
assessed in our study, possibly due to the short period of
ischemia of less than 12 hours and a reperfusion period of
only one hour. When the two groups were compared, the
numbers of apoptotic cells were equivalent for both the
ischemia and reperfusion periods.
One of the limitations of our study is the use of an
acellular solution instead of blood, which minimized the
effects of reperfusion injury. Blood perfusion would allow
the simulation of the interaction between circulating cells
and the pulmonary endothelium with all of the associated
consequences: leucocyte activation and migration, platelet
activation, thrombosis and the production of cytokines and
free oxygen radicals. The use of an acellular solution
explains why the mean LIS values for both groups were
relatively low. We chose not to use human blood, which
would lead to ethical issues in this type of research in
addition to significantly increasing the costs. Another
limitation of the study was the short reperfusion period.
However, these limitations do not weaken our conclusions
because the results are consistent and clinically significant.
The two preservation solutions were similar, as demon-
strated by the fact that the quality of lung preservation
obtained with LPDnac was the same as that obtained with
Perfadex. The EVLP system was shown to be a good tool to
perform pulmonary preservation studies for transplantation.
Further investigations should include the evaluation
of new preservation strategies, such as perfluorocarbon
Figure 4 - There was no statistically significant difference in the Lung Injury Score (LIS) between the groups over time (p=0.855). The
error bars represent the 95% CI.
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ventilation, surfactant administration and ex vivo perfusion
with antibiotics, thrombolytic agents and other drugs. The
inclusion of additives such as antioxidants in preservation
solutions may lead to the development of even better
preservation solutions.
ACKNOWLEDGMENTS
This work was supported by grants from FAPESP (Foundation for
Research Support of Sa˜o Paulo), Vitrolife (Go¨teborg, Sweden), Braile
Biome´dica (Sa˜o Jose´ do Rio Preto, Brazil) and Farmotera´pica (Sa˜o Paulo,
Brazil). The authors have no relevant financial relationships or conflicts of
interest to disclose.
AUTHOR CONTRIBUTIONS
Medeiros IL was responsible for the execution of the experimental
protocol, data analysis and paper production. Peˆgo Fernandes PM
supervised all stages and contributed to paper production. Mariani AW
was responsible for the execution of the experimental protocol and paper
production. Canzian M was responsible for the histopathological analysis.
Fernandes FG and Unterpertinger FV contributed to the execution of the
experimental protocol. Jatene FB supervised all stages. The authors had full
control of the design of the study, the methods used, the outcome
parameters and results, the analysis of the data and the production of the
written report.
REFERENCES
1. de Perrot M, Keshavjee S. Lung preservation. Chest Surg Clin N Am.
2003;13(3):443-62, http://dx.doi.org/10.1016/S1052-3359(03)00055-3.
2. Maccherini M, Keshafjee SH, Slutsky AS, Patterson GA, Edelson JD. The
effect of low-potassium dextran versus Euro-Collins solution for
preservation of isolated type II pneumocytes. Transplantation.
1991;52(4):621-6, http://dx.doi.org/10.1097/00007890-199110000-00008.
3. Bins OAR, DeLima NF, Buchanan SA, Cope JT, King RC, Marek CA, et al.
Both blood and crystalloid-based extracellular solutions are superior to
intracellular solutions for lung preservation. J Thorac Cardiovasc Surg.
1996;112(6):1515-21, http://dx.doi.org/10.1016/S0022-5223(96)70010-7.
4. Stru¨ber M, Hohlfeld JM, Fraund S, Kim P, Warnecke G, Haverich A.
Low-potassium-dextran solution ameliorates reperfusion injury of the
lung and protects surfactant function. J Thorac Cardiovasc Surg.
2000;120(3):566-72, http://dx.doi.org/10.1067/mtc.2000.107831.
5. Steen S, Sjo¨berg T, Pierre L, Liao Q, Eriksson L, Algotsson L.
Transplantation of lungs from a non-heart-beating donor. Lancet.
2001;357(9259):825-9, http://dx.doi.org/10.1016/S0140-6736(00)04195-7.
6. Steen S, Liao Q, Wierup PN, Bolys R, Pierre L, Sjo¨berg T. Transplantation
of lungs from non-heart-beating donors after functional assessment ex
vivo. Ann Thorac Surg. 2003;76(1):244-52; discussion 252, http://
dx.doi.org/10.1016/S0003-4975(03)00191-7.
7. Steen S, Ingemansson R, Eriksson L, Pierre L, Algotsson L, Wierup P,
et al. First human transplantation of a nonaccepTable donor lung after
reconditioning ex vivo. Ann Thorac Surg. 2007;83(6):2191-4, http://
dx.doi.org/10.1016/j.athoracsur.2007.01.033.
8. Pego-Fernandes PM, Medeiros IL, Mariani AW, Fernandes FG,
Unterpertinger FV, Samano MN, et al. Ex vivo lung perfusion: early
report of brazilian experience. Transplant Proc. 2010;42(2):440-3, http://
dx.doi.org/10.1016/j.transproceed.2010.01.015.
9. Aigner C, Seebacher G, Klepetko W. Donor selection. Chest Surg
Clin N Am. 2003;13(3):429-42, http://dx.doi.org/10.1016/S1052-3359(03)
00051-6.
10. Keshafjee SH, Yamazaki F, Cardoso PF, McRitchie DI, Patterson GA,
Cooper JD. A method for safe twelve-hour pulmonary preservation.
J Thorac Cardiovasc Surg. 1989;98(4):529-34.
11. Steen S, Kimblad PO, Sjo¨berg T, Lindberg L, Ingemansson R, Massa G.
Safe lung preservation for twenty-four hours with Perfadex. Ann Thorac
Surg. 1994;57(2):450-7, http://dx.doi.org/10.1016/0003-4975(94)91016-2.
12. Sommer SP, Warnecke G, Hohlfeld JM, Gohrbandt B, Niedermeyer J,
Kofidis T, et al. Pulmonary preservation with LPD and Celsior solution
in porcine lung transplantation after 24 h of cold ischemia. Eur J
Cardiothorac Surg. 2004;26(1):151-7.
13. Egan TM, Haithcock JA, Nicotra WA, Koukoulis G, Inokawa H, Sevala
M, et al. Ex vivo evaluation of human lungs for transplant suitability.
Ann Thorac Surg. 2006;81(4):1205-13, http://dx.doi.org/10.1016/
j.athoracsur.2005.09.034.
14. Cypel M, Rubacha M, Yeung J, Hirayama S, Torbicki K, Madonik M, et al.
Normothermic ex vivo perfusion prevents lung injury compared to
extended cold preservation for transplantation. Am J Transplant.
2009;9(10):2262-9.
15. Soares PRO, Braga KAO, Nepomuceno NA, Pazetti R, Correia AT,
Cardoso PFG, et al. Comparison between Perfadex and locally
manufactured low-potassium dextran solution for pulmonary preserva-
tion in an ex vivo isolated lung perfusion model. Transplant Proc.
2011;43(1):84-8, http://dx.doi.org/10.1016/j.transproceed.2010.12.005.
Comparison of lung preservation solutions
Medeiros IL et al.
CLINICS 2012;67(9):1101-1106
1106
